Pfizer Inc. (NYSE:PFE) Receives $28.50 Average Target Price from Analysts

Pfizer Inc. (NYSE:PFE) has earned a consensus rating of “Hold” from the twenty-one brokerages that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $28.50.

PFE has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. CICC Research started coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target for the company. Weiss Ratings restated a “hold (c)” rating on shares of Pfizer in a research note on Monday. Finally, Morgan Stanley boosted their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th.

Hedge Funds Weigh In On Pfizer

A number of hedge funds have recently modified their holdings of the business. Meridian Wealth Management LLC grew its position in Pfizer by 13.4% during the 2nd quarter. Meridian Wealth Management LLC now owns 103,774 shares of the biopharmaceutical company’s stock worth $2,500,000 after purchasing an additional 12,227 shares during the last quarter. Fort Sheridan Advisors LLC raised its holdings in shares of Pfizer by 3.3% in the second quarter. Fort Sheridan Advisors LLC now owns 120,987 shares of the biopharmaceutical company’s stock valued at $2,913,000 after buying an additional 3,917 shares during the last quarter. Centerpoint Advisors LLC boosted its stake in shares of Pfizer by 5,961.5% during the second quarter. Centerpoint Advisors LLC now owns 3,152 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 3,100 shares during the period. Mechanics Financial Corp raised its stake in Pfizer by 4.1% during the 2nd quarter. Mechanics Financial Corp now owns 20,403 shares of the biopharmaceutical company’s stock valued at $491,000 after acquiring an additional 810 shares during the last quarter. Finally, Ellis Investment Partners LLC raised its stake in Pfizer by 99.3% during the 2nd quarter. Ellis Investment Partners LLC now owns 17,062 shares of the biopharmaceutical company’s stock valued at $411,000 after acquiring an additional 8,501 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE opened at $25.76 on Friday. Pfizer has a 1 year low of $23.58 and a 1 year high of $28.75. The stock has a 50-day simple moving average of $25.01 and a 200-day simple moving average of $26.16. The stock has a market capitalization of $146.84 billion, a PE ratio of 33.90 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.38% and a net margin of 6.80%.Pfizer’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts predict that Pfizer will post 2.94 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s payout ratio is currently 131.30%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q2 results exceeded expectations. Pfizer reported adjusted earnings of $0.77 per share versus the $0.68 analyst consensus and revenue of $15.03 billion versus $14.40 billion expected. Revenue rose 2.6% year over year, led in part by strong demand for the blood thinner Eliquis. Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
• Positive Sentiment: Pfizer raised its 2026 revenue outlook. The company increased its revenue range to $60.5 billion-$62.5 billion from $59.5 billion-$62.5 billion, lifting the midpoint by $500 million while reaffirming adjusted EPS guidance of $2.80-$3.00. Growth from oncology, launched products and acquired medicines is helping offset weaker COVID sales. Pfizer tops quarterly estimates and hikes revenue guidance
• Positive Sentiment: Additional savings could support profitability. Pfizer targeted $2.5 billion in further cost reductions, expected to be implemented by 2029, as it works to improve efficiency and reduce reliance on older products. Pfizer targets additional cost cuts
• Positive Sentiment: Pipeline news adds potential upside. Pfizer reported positive Phase 3 data for Litfulo in vitiligo, while investors are also watching an obesity-treatment candidate and expanded oncology research for future growth catalysts. Pfizer reports positive Phase 3 Litfulo data
• Neutral Sentiment: Healthcare deal speculation and Pfizer’s acquisition activity remain additional factors investors are monitoring, but no transaction was confirmed in the reported coverage.
• Negative Sentiment: COVID vaccine and treatment demand continues to decline, and Pfizer still faces patent expirations and questions about whether its pipeline can replace lost blockbuster revenue. The quarter also included a reported net loss, while EPS guidance remains slightly below the analyst consensus.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.